Sinteza, antimikrobno i antitumorsko djelovanje nekoliko novih N-etil, N-benzil i N-benzoil-3-indolil heterocikličkih spojeva by ESLAM REDA EL-SAWY et al.
Chalcones, one of the major classes of natural products with widespread occurrence
in fruits, vegetables, spices and soy-based foodstuffs, have been reported to possess se-
veral biological activities (1, 2). Chalcones are suitable intermediates for the synthesis of
biologically active heterocyclic compounds, viz., pyrimidine, cyclohexanone, pyrazole
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A series of 1-(N-substituted-1H-indol-3-yl)-3-arylprop-2-
-ene-1-ones (2a,b-4a,b) were prepared and allowed to re-
act with urea, thiourea or guanidine to give pyrimidine
derivatives 5a,b-13a,b. Reaction of 2a,b-4a,b with ethyl
acetoacetate in the presence of a base gave cyclohexano-
ne derivatives 14a,b-16a,b. Reaction of the latter compo-
unds with hydrazine hydrate afforded indazole derivati-
ves 17a,b-19a,b. On the other hand, reaction of 2a,b-4a,b
with some hydrazine derivatives, namely hydrazine hy-
drate, acetyl hydrazine, phenylhydrazine and benzylhy-
drazine hydrochloride, led to the formation of pyrazole
derivatives 20a,b-31a,b. Moreover, reaction of 2a,b-4a,b
with hydroxylamine hydrochloride gave isoxazole deri-
vatives 32a,b-34a,b. The newly synthesized compounds
were tested for their antimicrobial activity and showed
that 4-(N-ethyl-1H-indol-3-yl)-6-(p-chlorophenyl)-pyrimi-
dine-2-amine (11b) was the most active of all the test com-
pounds towards Candida albicans compared to the refer-
ence drug cycloheximide. Eighteen new compounds, na-
mely pyrimidin-2(1H)-ones 5a,b-7a,b, pyrimidin-2(1H)-
-thiones 8a,b-10a,b and pyrimidin-2-amines 11a,b-13a,b
derivatives, were tested for their in vitro antiproliferative
activity against HEPG2, MCF7 and HCT-116 cancer cell
lines. 4-(N-ethyl-1H-indol-3-yl)-6-(p-methoxyphenyl)-pyri-
midin-2-amine (11a) was found to be highly active with
IC50 of 0.7 mmol L–1.
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and isoxazole derivatives (3–7). In addition, indole derivatives which form potent phar-
macodynamic nuclei have been reported to possess a wide variety of biological proper-
ties, viz., anti-inflammatory, anti-cancer and antimicrobial (8–10). Based on the above ob-
servations and in continuation of our research (9, 10), we herein report the synthesis of
some new N-substituted-3-indolylheterocycles for evaluating their antimicrobial and an-
ti-cancer activities starting from N-substituted-3-indolylchalcones.
EXPERMINTAL
Melting points were determined in open capillary tubes on an Electrothermal 9100
digital melting point apparatus (Büchi, Switzerland) and were uncorrected. Elemental
analyses were performed on a Perkin-Elmer 2400 analyzer (Perkin-Elmer, USA) and we-
re found within ± 0.4 % of the theoretical values. IR spectra were recorded on a Perkin-
-Elmer 1600 FTIR (Perkin-Elmer) in KBr discs. NMR spectra were measured with a Bru-
ker Avance spectrometer (300 and 125 MHz) (Bruker, Germany) in DMSO-d6, and chemi-
cal shifts were recorded in d ppm relative to TMS as internal standard solvent. Mass spec-
tra (EI) were run on a sector-field mass spectrometer (AMD M-40, AMD-Intectia GmbH,
Germany) and gas chromatograph-mass spectrometer, single phase, 200 V, 50/60 Hz, 30
A (Jeol, Japan). All reagents and solvents were of commercial grade.





phenyl)prop-2-ene-1-ones (3a), 1-(N-benzyl-1H-indol-3-yl)-3-(p-chlorophenyl)prop-2-ene-1- -ones
(3b), 1-(N-benzoyl-1H-indol-3-yl)-3-(p-methoxyphenyl)prop-2-ene-1-ones (4a) and 1-(N- -ben-
zoyl-1H-indol-3-yl)-3-(p-chlorophenyl)prop-2-ene-1-ones (4b). – To a solution of N-substitu-
ted-3-acetylindoles 1a, 1b or 1c (0.001 mol) and p-methoxybenzaldehyde or p-chlo- ro-
benzaldehyde (0.001 mol) in absolute ethanol (10 mL), an aqueous potassium hydroxide
solution (5 mL, 25 %) was added. The reaction mixture was stirred for 2 h at room tem-
perature and then left overnight in refrigerator. The reaction mixture was neutralized
with diluted hydrochloric acid (1:1) and the solid formed was filtered off, washed with




din-2(1H)-ones (6b), 4-(N-benzoyl-1H-indol-3-yl)-6-(p-methoxyphenyl) pyrimidin-2(1H)-ones
(7a) and 4-(N-benzoyl-1H-indol-3-yl)-6-(p-chlorophenyl)pyrimidin-2(1H)-ones (7b). – A mix-
ture of chalcones 2a,b, 3a,b or 4a,b (0.01 mol) and urea (0.6 g, 0.01 mol) in dry ethanol
(10 mL) containing glacial acetic acid (0.5 mL) was refluxed for 6–8 h. After cooling, the
reaction mixture was poured onto ice-water (50 mL) and the solid formed was filtered
off, air dried and recrystallized from absolute ethanol.
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4-(N-Ethyl-1H-indol-3-yl)-6-(p-methoxyphenyl)pyrimidin-2(1H)-thiones (8a), 4-(N-ethyl-
-1H-indol-3-yl)-6-(p-chlorophenyl)pyrimidin-2(1H)-thiones (8b), 4-(N-benzyl-1H-indol-3-yl)- -6-
-(p-methoxyphenyl)pyrimidin-2(1H)-thiones (9a), 4-(N-benzyl-1H-indol-3-yl)-6-(p-chlorophe-
nyl) pyrimidin-2(1H)-thiones (9b), 4-(N-benzoyl-1H-indol-3-yl)-6-(p-methoxyphenyl)pyrimidin-
-2(1H)-thiones (10a) and 4-(N-benzoyl-1H-indol-3-yl)-6-(p-chlorophenyl)pyrimidin-2(1H)-
-thiones (10b). – A mixture of chalcones 2a,b, 3a,b or 4a,b (0.01 mol) and thiourea (0.76 g,
0.01 mol) in dry ethanol (10 mL) containing glacial acetic acid (0.5 mL) was refluxed for
6–8 h. After cooling, the reaction mixture was poured onto ice-water (50 mL) and the




ne-2-amines (12b), 4-(N-benzoyl-1H-indol-3-yl)-6-(p-methoxyphenyl) pyrimidine-2-amines (13a)
and 4-(N-benzoyl-1H-indol-3-yl)-6-(p-chloro-phenyl)pyrimidine-2-amines (13b). – A mixture of
chalcones 2a,b, 3a,b or 4a,b (0.01 mol), guanidine hydrochloride (0.96 g, 0.01 mol) and
anhydrous sodium acetate (0.82 g, 0.01 mol) in dry ethanol (15 mL) was refluxed for 2–3 h.








A mixture of chalcones 2a,b, 3a,b or 4a,b (0.01 mol) and ethyl acetoacetate (1.30 mL, 0.01
mol) in absolute ethanol (15 mL) containing aqueous potassium hydroxide solution
(1 mL, 10 %) was refluxed for 2 h and then left overnight at room temperature. The solid





-methoxyphenyl)-6-(N-benzoyl-1H-indol-3-yl)-2H-indazol-3(H)ones (19a) and 4,5-dihydro-4-(p-
-chlorophenyl)-6-(N-benzoyl-1H-indol-3-yl)-2H-indazol-3(H)ones (19b). – A mixture of com-
pound 14a,b, 15a,b or 16a,b (0.1 mol) and hydrazine hydrate 99 % (5 mL, 0.1 mol) in ab-
solute ethanol (15 mL) containing glacial acetic acid (0.5 mL) was refluxed for 2 h. After
cooling, the solid formed was filtered off, air dried and recrystallized from chloroform.
4,5-Dihydro-3-(N-ethyl-1H-indol-3-yl)-5-(p-methoxyphenyl)pyrazoles (20a), 4,5-dihydro-3-
-(N-ethyl-1H-indol-3-yl)-5-(p-chlorophenyl) pyrazoles (20b), 4,5-dihydro-3-(N-benzyl-1H-in-
dol-3-yl)-5-(p-methoxyphenyl)pyrazoles (21a), 4,5-dihydro-3-(N-benzyl-1H-indol-3-yl)-5-(p-chloro-
phenyl)pyrazoles (21b), 4,5-dihydro-3-(N-benzoyl-1H-indol-3-yl)-5-(p-methoxyphenyl)pyrazo-
les (22a) and 4,5-dihydro-3-(N-benzoyl-1H-indol-3-yl)-5-(p-chlorophenyl)pyrazoles (22b). – To
a solution of compound 2a,b, 3a,b or 4a,b (0.01 mol) in absolute ethanol (10 mL) contain-
ing glacial acetic acid (0.5 mL), hydrazine hydrate 99 % (1 mL, 0.02 mol) was added. The
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reaction mixture was refluxed for 4 h. After cooling, the reaction mixture was poured






-indol-3-yl)-5-(p-methoxyphenyl)-N-acetylpyrazoles (25a) and 4,5-dihydro-3-(N-benzoyl-1H-
-indol-3-yl)-5-(p-chlorophenyl)-N-acetylpyrazoles (25b). – Method A. – To a solution of com-
pound 2a,b, 3a,b or 4a,b (0.01 mol) in a mixture of (15 mL) acetic anhydride and glacial
acetic acid (2:1), hydrazine hydrate 99 % (1 mL, 0.02 mol) was added. The reaction mix-
ture was refluxed for 6-8 h. After cooling, the reaction mixture was poured onto ice-wa-
ter (50 mL) and the solid formed was filtered off, air dried and recrystallized from aque-
ous ethanol. Method B. – A mixture of compound 2a,b, 3a,b or 4a,b (0.01 mol) and acetyl
hydrazine (0.74 g, 0.01 mol) in absolute ethanol (10 mL) containing glacial acetic acid
(0.5 mL) was refluxed for 2 h. After cooling, the solid formed was filtered off, air dried





-1H-indol-3-yl)-5-(p-methoxyphenyl)-N-phenylpyrazoles (28a) and 4,5-dihydro-3-(N-benzoyl-
-1H-indol-3-yl)-5-(p-chlorophenyl)-N-phenylpyrazoles (28b). – A mixture of compound 2a,b,
3a,b or 4a,b (0.01 mol) and phenylhydrazine (1.08 mL, 0.01 mol) in absolute ethanol
(10 mL) containing glacial acetic acid (0.5 mL) was refluxed for 2 h. After cooling, the





-indol-3-yl)-5-(p-methoxyphenyl)-N-benzylpyrazoles (31a) and 4,5-dihydro-3-(N-benzoyl-1H-
-indol-3-yl)-5-(p-chlorophenyl)-N-benzylpyrazoles (31b). – A mixture of compound 2a,b, 3a,b
or 4a,b (0.01 mol), benzylhydrazine hydrochloride (1.95 g, 0.01 mol) and anhydrous sodi-
um acetate (0.67 g, 0.015 mol) in dry ethanol (15 mL) was refluxed for 2–3 h. After cool-
ing, the solid formed was filtered off, air dried and recrystallized from absolute ethanol.
4,5-Dihydro-3-(N-ethyl-1H-indol-3-yl)-5-(p-methoxyphenyl)isoxazoles (32a), 4,5-dihydro-
-3-(N-ethyl-1H-indol-3-yl)-5-(p-chlorophenyl) isoxazoles (32b), 4,5-dihydro-3-(N-benzyl-1H-in-
dol-3-yl)-5-(p-methoxyphenyl)isoxazoles (33a), 4,5-dihydro-3-(N-benzyl-1H-indol-3-yl)-5-(p-
-chlorophenyl)isoxazoles (33b), 4,5-dihydro-3-(N-benzoyl-1H-indol-3-yl)-5-(p-methoxyphenyl)-
isoxazoles (34a) and 4,5-dihydro-3-(N-benzoyl-1H-indol-3-yl)-5-(p-chlorophenyl)isoxazoles (34b).
– A mixture of compound 2a,b, 3a,b or 4a,b (0.01 mol), hydroxylamine hydrochloride
(0.69 g, 0.01 mol) and anhydrous sodium acetate (0.67 g, 0.01 mol) in absolute ethanol
(10 mL) was refluxed for 6–8 h. After cooling, the reaction mixture was poured onto ice-
-water (50 mL). The solid that formed was filtered off, air dried and recrystallized from
absolute ethanol.
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Biological assay
Antimicrobial evaluation. – Antimicrobial activity of the synthesized compounds was
determined in vitro by the disc diffusion method (12) against a variety of pathogenic mi-
croorganisms: Salmonella typhimurium (ATCC 14028), Pseudomonas fluorescens (S 97) (Gram-
-positive bacteria), Staphylococcus aureus (ATCC 25923), Bacillus subtilis (ATCC 6635) (Gram-
-negative bacteria) and two strains of fungi, Candida albicans (ATCC 10231) and Asper-
gillus fumigatus (identified microscopically according to Moubasher (13). Antimicrobial
activities of the tested compounds were estimated by placing presterilized filter paper
discs (6 mm in diameter) impregnated with two doses of test compounds (10 and 20 mg
per disc) on Nutrient and MacConky agar media for bacteria and on Sabouraud dex-
trose agar for fungus. Dimethyl formamide (DMF) was used as a solvent for impregna-
tion. Inhibition zones (IZ) of the test compounds were measured after 24–48 h incuba-
tion at 37 °C for bacteria and after 5 days incubation at 28 °C for fungi. Chloramphenicol
and cephalothin were used as a reference drugs for bacteria, whereas, cycloheximide
(Sigma-Aldrich, USA) was used as reference drug for fungi.
Cell culture. – HEPG2 (human liver carcinoma), MCF7 (human breast cancer) and
HCT-116 (human colon cancer) cell lines were obtained from the Karolinska Institute,
Stockholm, Sweden. All cells were maintained in RPMI 1640 medium, except for the MCF7
cancer cells which were maintained in DMEM medium (Lonza Biowahittkar, Belgium).
All the media were supplemented with 1 % antibiotic-antimycotic mixture (10,000 U mL–1
potassium penicillin, 10,000 mg mL–1 streptomycin sulfate, 25 mg mL–1 amphotericin B
and 1 % L-glutamine (Biowest, USA).
MTT cytotoxicity assay. – Cell viability was investigated using MTT [3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Bio Basic Canada Inc., Canada) assay (14).
This reaction depends on the mitochondrial reduction of yellow MTT into purple forma-
zan. All the preceding steps were carried out in a sterile laminar air flow cabinet Bio-
safety class II level (Baker, SG403INT, USA). All incubations were done at 37 °C in 5 %
CO2 incubator in humidified atmosphere (Sheldon, TC2323, USA). Cells were seeded
into 96-well microtiter plastic plates at a concentration of (104 cells per well) and allo-
wed to adhere for 24 hours. Medium was aspirated and fresh medium (without serum)
was added to the cells with various concentrations of test compounds (10, 5, 2.5 and 1.25
mg mL–1 in DMSO) and incubated for 48 hours. Medium was aspirated and 40 mL MTT
salt (2.5 mg mL–1) was added to each well and incubated for further 4 hours. To stop the
reaction and dissolve any formed formazan crystals, 200 mL of 10 % sodium dodecyl sul-
fate (SDS) was added to each well and incubated overnight at 37 °C. The amount of for-
mazan producted was measured at 595 nm with a reference wavelength of 620 nm as
background using a microplate reader (Bio-Rad Laboratories, model 3350, USA). For un-
treated cells (negative control), medium was added instead of test compounds. A posi-
tive control Adrinamycin® (doxorubicin) (Mr = 579.9) was used as a known cytotoxic
natural agent giving 100 % inhibition. Dimethyl sulfoxide (DMSO) was the vehicle used
for dissolution of the tested compound and its final concentration on the cells was less
than 0.2 %.
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IC50 was calculated for the samples and negative control (cells with vehicle) by the
probit analysis method using a simple t-test (SPSS statistical analysis software package/
version 11.0, SPPS Inc., (IL), Chicago, USA).
RESULTS AND DISCUSSION
Chemistry
The starting chalcones, namely, 1-(N-ethyl-1H-indol-3-yl)-3-arylprop-2-ene-1-ones
(2a,b), 1-(N-benzyl-1H-indol-3-yl)-3-arylprop-2-ene-1-ones (3a,b) and 1-(N-benzoyl-1H-in-
dol-3-yl)-3-arylprop-2-ene-1-ones (4a,b), were synthesized via the Claisen-Schmidt reac-
tion of N-ethyl (1a), N-benzyl (1b) and N-benzoyl-3-acetylindoles (1c), respectively, with
p-methoxybenzaldehyde and/or p-chlorobenzaldehyde in ethanol and in the presence of
aqueous potassium hydroxide 25 % (Scheme 1).
Cyclocondensation of chalcones 2a,b, 3a,b or 4a,b with urea in dry ethanol and in
the presence of glacial acetic acid as a catalyst gave 4-(N-substituted-1H-indol-3-yl)-6-
-arylpyrimidin-2(1H)-ones (5a,b), (6a,b) and (7a,b), respectively. Similarly, the reaction
of chalcones 2a,b, 3a,b or 4a,b with thiourea gave pyrimidin-2(1H)-thiones 8a,b, 9a,b and
10a,b, respectively. Moreover, the reaction of chalcones 2a,b, 3a,b or 4a,b with guanidine
hydrochloride in dry ethanol and in the presence of anhydrous sodium acetate yielded
4-(N-substituted-1H-indol-3-yl)-6-aryl-pyrimidine-2-amines (11a,b), (12a,b) and (13a,b),
respectively (Scheme 1).
It was reported previously that the base catalyzed reaction of chalcone with ethyl
acetoacetate gave rise to cyclohexanone (7, 15). In the present work and under the above
mentioned conditions, the new chalcones 2a,b, 3a,b or 4a,b were allowed to react with
ethyl acetoacetate (1:1) in the presence of aqueous potassium hydroxide 10 % to give new
compounds, namely ethyl-4-(N-substituted-1H-indol-3-yl)-6-aryl-2-oxocyclohexa-3-ene-
-carboxylates (14a,b), (15a,b) and (16a,b), respectively (Scheme 1).
Reaction of compound 14a with hydrazine hydrate under reflux in ethanol in the
presence of glacial acetic acid gave a compound with molecular ion peak at m/z = 385 (7 %).
Its IR (KBr) spectrum showed characteristic absorption bands at 3210 (NH), 1645 (C=O),
1620 (C=N), 1577 (C=C) and 1009 cm-1 (C-O-C). Its 1H NMR (DMSO-d6) lacked the sig-
nals at 4.42 and 1.61 ppm of COOCH2CH3 and revealed signals at 9.21 (s, 1H, NH), 8.02
(s, 1H, H-2 indole), 7.97–7.01 (m, 8H, ArH), 6.16 (s, 1H, CH=C), 4.21 (q, 2H, CH3CH2N),
3.91 (s, 3H, OCH3), 2.90 and 3.31 (2d, 2H, CHCH), 2.13 and 2.45 (dd, 2H, CHCH2), 1.30
ppm (t, 3H, CH3CH2N). Its 13C NMR (DMSO-d6) revealed signals at 177.3 (C=O),
111.1–152.1 (ArC), 52.6 (CH2), 42.6 (CH) and 15.1 ppm (CH3).
Based on these data, the assigned structure of the product was proposed as 4,5-di-
hydro-4-(p-methoxyphenyl)-6-(N-ethyl-1H-indol-3-yl)-2H-indazol-3(H)one (17a) (Scheme 1).
The reaction may have proceeded through condensation between C=O of cyclohexanone
and NH2 of hydrazine, followed by cyclization by loosing a molecule of ethanol. Simi-
larly, reaction of 14b, 15a,b or 16a,b with hydrazine hydrate under the above mentioned
conditions led to the formation of 4,5-dihydro-4-aryl-6-(N-substituted-1H-indol-3-yl)-2H-
-indazol-3(H)one 17b, 18a,b, and 19a,b (Scheme 1).
162
E. R. El-Sawy et al.: Synthesis, antimicrobial and anti-cancer activities of some new N-ethyl, N-benzyl and N-benzoyl-3-indolyl hete-
rocycles, Acta Pharm. 62 (2012) 157–179.
On the other hand, condensation of chalcones 2a,b, 3a,b or 4a,b with hydrazine hy-
drate in absolute ethanol and in the presence of a few drops of glacial acetic acid af-
forded 4,5-dihydro-3-(N-substituted-1H-indol-3-yl)-5-arylpyrazoles 20a,b, 21a,b and 22a,b,
respectively (Scheme 2), whereas reaction of 2a,b, 3a,b or 4a,b with hydrazine hydrate
under reflux in a mixture of acetic anhydride and glacial acetic acid (2:1) afforded the
corresponding N-acetylpyrazole derivatives 23a,b, 24a,b and 25a,b, respectively (Sche-
me 2). Also, compounds 23a,b, 24a,b and 25a,b were obtained via the reaction of 2a,b,
3a,b or 4a,b with acetyl hydrazine in refluxing absolute ethanol, which showed no de-
pression in admixed melting points with that previously obtained (Scheme 2).
In addition, reaction of 2a,b, 3a,b or 4a,b with phenylhydrazine gave N-phenylpy-
razole derivatives 26a,b, 27a,b and 28a,b, respectively (Scheme 2). Also, reaction of 2a,b,
3a,b or 4a,b with benzylhydrazine hydrochloride in the presence of anhydrous sodium ace-
tate gave N-benzylpyrazole derivatives 29a,b, 30a,b and 31a,b, respectively (Scheme 2).
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1 a: R = CH2CH3
b: R = CH2Ph








Furthermore, reaction of 2a,b, 3a,b or 4a,b with hydroxylamine hydrochloride in the
presence of anhydrous sodium acetate led to the formation of 4,5-dihydro-3-(N-substi-
tuted-1H-indol-3-yl)-5-aryl-isoxazoles (32a,b), (33a, b) and (34a,b), respectively (Scheme 2).
Structures of the newly synthesized compounds were confirmed on the basis of ele-
mental analyses (Table I) as well as IR, NMR, and MS spectral data (Table II).
Biological activity
All the newly synthesized compounds were tested for their antimicrobial activity
against a variety of pathogenic microorganisms using the disk diffusion method (12) at
two doses of 10 and 20 mg per disc (Table III). None of the test compounds showed anti-
microbial activity at the dose of 10 mg per disc, whereas at the dose of 20 mg per disc
compound 4-(N-ethyl-1H-indol-3-yl)-6-(p-chlorophenyl) pyrimidine-2-amine (11b) was
found to be the most active of all the test compounds, with of 33 mm against Candida
albicans, compared to the reference drug cycloheximide (39 mm).
Eighteen new compounds, namely pyrimidin-2(1H)-ones 5a,b-7a,b, pyrimidin-2(1H)-
-thiones 8a,b-10a,b and pyrimidin-2-amines 11a,b-13a,b were preliminarily screened for
164
E. R. El-Sawy et al.: Synthesis, antimicrobial and anti-cancer activities of some new N-ethyl, N-benzyl and N-benzoyl-3-indolyl hete-
















































E. R. El-Sawy et al.: Synthesis, antimicrobial and anti-cancer activities of some new N-ethyl, N-benzyl and N-benzoyl-3-indolyl hete-
rocycles, Acta Pharm. 62 (2012) 157–179.





























































































84–6 80 76.63/76.70 5.46/5.65 13.78/13.88
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132–4 40 68.94/68.76 5.51/5.67 11.49/11.56
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173–5 74 71.91/71.75 4.27/4.55 6.99/7.11
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1H and 13C NMR
(d, ppm)
Mass (m/z, %)
2a 1634 (C=O), 1570
(C=C), 1025 (C-O-C)
2b 1641 (C=O), 1617
(C=C), 746 (C-Cl)
1H NMR: 8.35 (s, 1H, H-2 indole),
7.89–7.78 (m, 4H, ArH indole), 7.63 &
7.51 (2d, 2H, CH=CH), 7.31–7.23 (m,
4H, ArPh), 4.35 (q, 2H, CH2), 1.51
(t, 3H, CH3)
3a 1739 (C=O), 1634
(C=C), 1017 (C-O-C)
1H NMR: 8.21 (s, 1H, H-2 indole),
7.01–7.65 (m, 13H, ArH), 7.00 & 6.91
(2d, 2H, CH=CH), 5.6 (s, 2H, CH2),
3.82 (s, 3H, OCH3)
3b 1738 (C=O), 1638
(C=C), 735 (C-Cl)
4a 1742 & 1674 (C=O),
1570 (C=C), 1020
(C-O-C)
1H NMR: 8.28 (s, 1H, H-2 indole), 8.15
& 7.46 (2d, 2H, CH=CH), 7.22–7.13
(m, 13H, ArH), 3.82 (s, 3H, OCH3)
4b 1693 & 1635 (C=O),
1570 (C=C), 748 (C-Cl)
5a 3429 (NH), 1639 (C=O),
1572 (C=N), 1554
(C=C), 1024 (C-O-C)
345 (M+, 21), 315 (20),
238 (10), 143 (100),
117 (50), 109 (17)
5b 3480 (NH), 1643 (C=O),
1585 (C=N), 1545
(C=C), 739 (C-Cl)
1H NMR: 8.75 (s, 1H, NH), 8.33
(s, 1H, H-2 indole), 7.87–7.24 (m,
9H, ArH), 4.31 (q, 2H, CH2),
1.48 (t, 3H, CH3)
6a 3445 (NH), 1638 (C=O),
1605 (C=N), 1568
(C=C), 1020 (C-O-C)
407 (M+, 1), 206 (2),
202 (1), 191 (1), 115
(30), 91 (100)
6b 3327 (NH), 1624 (C=O),
1602 (C=N), 1557
(C=C), 751 (C-Cl)
1H NMR: 8.98 (s, 1H, NH), 8.56
(s, 1H, H-2 indole), 8.37 (d, 1H, H-7
indole), 7.90–7.20 (m, 13H, ArH),
5.55 (s, 2H, CH2)
13C NMR: 157.6 (C=O), 137.8–109.6
(ArC), 61.6 (CH2N)
411 (M+, 5), 413
(M++2, 0.15), 373 (35),
371 (100), 343 (46),
217 (26)
7a 3457 (NH), 1744 (C=O),
1614 (C=N), 1571
(C=C), 1021 (C-O-C)
1H NMR: 11.87 (s, 1H, NH), 8.68
(s, 1H, H-2 indole) 8.29 (d, 1H, H-7
indole), 7.81–7.00 (m, 13H, ArH),
3.82 (s, 3H, OCH3)
7b




425 (M+, 0.02), 427
(M++2, 0.006), 283
(34), 281 (100), 144
(76), 117 (29), 116 (43)
8a 3417 (NH), 1638 (C=N),
1572 (C=C), 1249
(C=S), 1055 (C-O-C)
361 (M+, 2), 316 (20),
238 (10), 142 (100),
116 (50), 77 (17)
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8b 3414 (NH), 1644 (C=N),
1585 (C=C), 1240
(C=S), 775 (C-Cl)
1H NMR: 12.09 (s, 1H, NH), 8.36
(s, 1H, H-2 indole), 7.86–7.23
(m, 9H, ArH), 4.33 (q, 2H, CH2),
1.51 (t, 3H, CH3)
365 (M+, 1), 367
(M++2, 0.015), 309 (24),
311 (8), 281 (38), 144
(28), 116 (20) 91 (100)
9a 3445 (NH), 1637 (C=N),
1606 (C=C), 1251
(C=S), 1020 (C-O-C)
423(M+, 10), 367 (40),
276 (18), 204 (11), 91
(100)
9b 3383 (NH), 1637 (C=N),
1572 (C=C), 1226
(C=S), 736 (C-Cl)
427 (M+, 10), 429
(M++2, 3), 371 (100),
345 (13), 343 (37), 207
(5), 115 (3)




1H NMR: 8.71 (s, 1H, NH), 8.35
(s, 1H, H-2 indole), 8.19 (d, 1H, H-7
indole), 7.82 (d, 1H, H-4 indole),
7.71–7.01 (m, 12H, ArH), 3.82
(s, 3H, OCH3)
13C NMR: 192.6 (C=O), 182.7 (C=S),
167.4 (C=N), 160.2–110.0 (ArC), 54.8
(OCH3)
437 (M+, 1), 277 (100),
249 (12), 144 (40), 117
(12), 116 (14)




1H NMR: 8.75 (s, 1H, NH), 8.21 (s,
1H, H-2 indole), 7.87–7.01 (m, 14H,
ArH)
11a 3440 (NH2), 1620
(C=N), 1578 (C=C),
1009 (C-O-C)
1H NMR: 10.50 (s, 2H, NH2), 8.22 (s,
1H, H-2 indole), 8.01–7.00 (m, 9H,
ArH), 4.45 (q, 2H, CH2), 3.94 (s, 3H,
OCH3), 1.96 (t, 3H, CH3)
13C NMR: 161.4 (C=N), 160.2–110.0
(ArC), 54.8 (CH2), 42.4 (OCH3), 15.7
(CH3)
11b 3445 (NH2), 1621
(C=N), 1588 (C=C),
745 (Cl)
348 (M+, 10), 350
(M++2, 3), 144 (100),
116 (60), 111 (50), 77
(70)
12a 3300 (NH2), 1621
(C=N), 1590 (C=C),
1019 (C-O-C)
1H NMR: 9.55 (s, 2H, NH2), 8.02 (s,
1H, H-2 indole), 8.00–7.00 (m, 14H,
ArH), 5.65 (s, 2H, CH2), 3.94 (s, 3H,
OCH3)
13C NMR: 161.4 (C=N), 161.0–111.0
(ArC), 56.7 (CH2), 42.1 (CH3)
12b 3445 (NH2), 1621
(C=N), 1575 (C=C),
748 (Cl)
410 (M+, 17), 412
(M++2, 9), 142 (100),
115 (60), 111 (50), 77
(70)




1H NMR: 9.71 (s, 2H, NH2), 8.02 (s,
1H, H-2 indole), 7.70–7.00 (m, 14H,
ArH), 3.94 (s, 3H, OCH3)
13C NMR: 182.0 (C=O), 157.4 (C=N),
155.7–111.0 (ArC), 41.1 (CH3)
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13b 3345 (NH2), 1678
(C=O), 1621 (C=N),
1575 (C=C), 748 (Cl)
424 (M+, 11), 426
(M++2, 3), 193 (10),
144 (100), 115 (60),
111 (50), 77 (70)
14a 1703 & 1687 (2C=O),
1599 (C=C), 1009
(C-O-C)
1H NMR: 8.21 (s, 1H, H-2 indole),
7.87–7.01 (m, 8H, ArH), 6.68 (s, 1H,
CH=C), 4.42 (q, 2H, CH2CO), 4.21
(q, 2H, CH2-N), 3.91 (s, 3H, OCH3),
3.55–2.69 (m, 4H, -CHCHCH2
cyclohexanone), 1.61 (t, 3H,
CH3CH2CO), 1.30 (t, 3H, CH3CH2N)
13C NMR: 182.1 & 177.3 (2C=O),
111.1–152.1 (ArC), 61.3 (CH2CO),
52.6 (CH2N), 42.6 (CH), 15.1 (2CH3)
14b 1736 & 1701 (2C=O),
1557 (C=C), 747 (Cl)
1H NMR: 8.21 (s, 1H, H-2 indole),
7.81–7.01 (m, 8H, ArH), 6.66 (s, 1H,
CH=C), 4.44 (q, 2H, CH2CO), 4.21
(q, 2H, CH2-N), 3.57–2.61 (m, 4H,
CHCHCH2 cyclohexanone), 1.61
(t, 3H, CH3CH2CO), 1.21 (t, 3H,
CH3CH2N)
15a 1721 & 1699 (2C=O),
1578 (C=C), 1010
(C-O-C)
1H NMR: 8.21 (s, 1H, H-2 indole),
7.81–7.01 (m, 13H, ArH), 6.68 (s, 1H,
CH=C), 5.55 (s, 2H, CH2), 4.43 (q, 2H,
CH2CO), 3.99 (s, 3H, OCH3), 3.56–2.67
(m, 4H, CHCHCH2 cyclohexanone),
1.9 (t, 3H, CH3CH2CO)
15b 1707 & 1689 (2C=O),
1566 (C=C), 745 (Cl)
1H NMR: 8.11 (s, 1H, H-2 indole),
7.81–7.01 (m, 13H, ArH), 6.68 (s, 1H,
CH=C), 5.56 (s, 2H, CH2), 4.43 (q, 2H,
CH2CO), 3.88–2.51 (m, 4H, CHCHCH2
cyclohexanone), 1.9 (t, 3H,
CH3CH2CO)
16a 1721, 1703 & 1689
(3C=O), 1577 (C=C),
1008 (C-O-C)
1H NMR: 8.21 (s, 1H, H-2 indole),
7.81–7.01 (m, 13H, ArH), 6.68 (s, 1H,
CH=C), 4.43 (q, 2H, CH2CO), 3.99
(s, 3H, OCH3), 3.56–2.67 (m, 4H,
CHCHCH2 cyclohexanone), 1.9
(t, 3H, CH3CH2CO)
16b 1723, 1705 & 1678
(3C=O), 1588 (C=C),
748 (Cl)
1H NMR: 8.11 (s, 1H, H-2 indole),
7.81–7.01 (m, 13H, ArH), 6.66 (s, 1H,
CH=C), 4.42 (q, 2H, CH2CO),
3.88–2.51 (m, 4H, CHCHCH2
cyclohexanone), 1.61 (t, 3H,
CH3CH2CO)
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17a 3340 (NH), 1645 (C=O),
1620 (C=N), 1577
(C=C), 1009 (C-O-C)
1H NMR: 9.21 (s, 1H, NH), 8.02 (s,
1H, H-2 indole), 7.97–7.01 (m, 8H,
ArH), 6.16 (s, 1H, CH=C), 4.21 (q, 2H,
CH2N), 3.91 (s, 3H, OCH3), 2.90 &
3.31 (2d, 2H, CHCH), 2.13 & 2.45
(2dd, 2H, CHCH2), 1.30 (t, 3H,
CH3CH2N)
13C NMR: 177.3 (C=O), 111.1–152.1
(ArC), 52.6 (CH2), 42.6 (CH), 15.1
(CH3)
385 (M+, 7), 350 (10),
308 (30), 141 (100),
117(18), 77 (60)
17b 3300 (NH), 1665 (C=O),
1621 (C=N), 1578
(C=C), 745 (Cl)
389 (M+, 7), 391
(M++2, 1), 144 (100),
142 (10), 117 (60), 111
(50), 77 (70)
18a 3320 (NH), 1660 (C=O),
1643 (C=N), 1567
(C=C), 1018 (C-O-C)
1H NMR: 8.71 (s, 1H, NH), 8.02 (s,
1H, H-2 indole), 7.77–7.01 (m, 13H,
ArH), 6.22 (s, 1H, CH=C), 5.56 (s, 2H,
CH2-N), 3.91 (s, 3H, OCH3), 2.81 &
3.43 (2d, 2H, CHCH) 2.11 & 2.55 (2dd,
2H, CHCH2)
18b 3218 (NH), 1675 (C=O),
1621 (C=N), 1577
(C=C), 754 (Cl)
451 (M+, 10), 453
(M++2, 2), 142 (10),
117 (60), 111 (50), 91
(100), 77 (70)
19a 3298 (NH), 1687 (C=O),
1621 (C=N), 1567
(C=C), 1019 (C-O-C)
1H NMR: 8.71 (s, 1H, NH), 8.02 (s,
1H, H-2 indole), 7.77–7.01 (m, 13H,
ArH), 6.22 (s, 1H, CH=C), 3.98 (s, 3H,
OCH3), 2.81 & 3.43 (2d, 2H, CHCH)
2.11 & 2.55 (2dd, 2H, CHCH2)
19b 3200 (NH), 1678 (C=O),
1619 (C=N), 1587
(C=C), 745 (Cl)
465 (M+, 10), 467
(M++2, 2), 193 (100),
142 (10), 111 (50), 77
(70)
20a 3332 (NH), 1583
(C=N), 1523 (C=C),
1013 (C-O-C)
1H NMR: 8.52 (s, 1H, H-2 ind.), 8.03
(s, 1H, NH), 7.82–7.17 (m, 8H, ArH),
4.31(q, 2H, CH2N), 3.81 (s, 3H, OCH3),
3.74 (dd, 1H, CH-pyrazoline), 2.58
(dd, 1H, CH2-pyrazoline equatorial),
1.44 (dd, 1H, CH2-pyrazoline axial),
1.05 (t, 3H, CH3)
319 (M+, 12), 317 (11),
172 (100), 170 (31),
156 (12), 145 (23), 115
(18)
20b 3255 (NH), 1618 (C=N),
1523 (C=C), 746 (C-Cl)
323 (M+, 2), 325
(M++2, 0.01), 144
(100), 130 (12), 116
(31), 111 (9)
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21a 3400 (NH), 1587
(C=N), 1545 (C=C),
1021 (C-O-C)
1H NMR: 10.22 (s, 1H, NH), 8.53 (s,
1H, H-2 indole), 7.51–7.17 (m, 13H,
ArH), 5.55 (s, 2H, CH2), 3.86 (dd,
1H, CH-pyrazoline), 3.74 (s, 3H,
OCH3), 2.57 (dd, 1H, CH2-pyrazoline
equatorial), 1.55 (dd, 1H,
CH2-pyrazoline axial)
13C NMR: 157.6 (C=N), 136.6–109.9
(ArC), 40.6 (CH2N), 15.5 (CH3)
381(M+, 62), 366 (1),
91 (100), 77 (6), 65
(16)
21b 3265 (NH), 1606 (C=N),
1580 (C=C), 734 (C-Cl)
1H NMR: 10.21 (s, 1H, NH), 8.20 (s,
1H, H-2 indole), 7.75–7.12 (m, 13H,
ArH), 5.51 (s, 2H, CH2), 5.42 (dd, 1H,
CH-pyrazoline), 4.76 (dd, 1H,
CH2-pyrazoline equatorial), 2.58 (dd,
1H, CH2-pyrazoline axial)
13C NMR: 139.5–110.6 (ArC), 41.2
(CH2Ph), 15.0 (CH2)
22a 3392 (NH), 1664 (C=O),
1582 (C=N), 1545
(C=C), 1012 (C-O-C)
395 (M+, 1), 314 (100),
144 (3), 142 (23), 117
(5), 89 (11)
22b 3391 (NH), 1722 (C=O),
1618 (C=N), 1521
(C=C), 747 (C-Cl)
399 (M+, 2), 401
(M++2, 0.15), 295 (30),
293 (100), 258 (5)
23a 1719 (C=O), 1640
(C=N), 1572 (C=C),
1042 (C-O-C)
361 (M+, 1), 305 (42),
277 (13), 172 (100),
145 (19),130 (7), 116
(20)
23b 1725 C=O), 1648
(C=N), 1614 (C=C),
783 (C-Cl)
365 (M+, 1), 367
(M++2, 0.015),313 (34),
309 (100), 281 (53),
172 (58), 144 (20), 117
(3)
24a 1741 (C=O), 1639
(C=N), 1604 (C=C),
1023 (C-O-C)
423 (M+, 0.01) and
249 (100)
Diagram 37
24b 1723 (C=O), 1639
(C=N), 1575 (C=C),
736 (C-Cl)
1H NMR: 8.56 (s, 1H, H-2 indole),
8.37 (d, 1H, H-7 indole), 8.21 (d, 1H,
H-4 indole), 7.91–7.15 (m, 11H, ArH),
5.55 (s, 2H, CH2N), 5.51 (dd, 1H,
CH-pyrazoline), 2.51 (dd, 1H,
CH2-pyrazoline equatorial), 1.23 (dd,
1H, CH2-pyrazoline axial), 1.19 (s, 3H,
CH3)
13C NMR: 182.8 (C=O), 138.1–110.7
(ArC), 41.2 (CH2), 15.1 (CH3)
427 (M+, 0.01), 429
(M++2, 0.003), 372
(34), 371 (89), 345
(14), 115 (7), 91 (100)
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25a 1724 (C=O), 1647
(C=N), 1615 (C=C),
1028 (C-O-C)
437 (M+, 1), 367 (32),
333 (13), 277 (100), 91
(80), 57 (25)
25b 1723 C=O), 1646
(C=N), 1590 (C=C),
777 (C-Cl)
441 (M+, 13), 443
(M++2, 4), 298 (43),
296 (100), 261 (13),
186 (13)
26a 1620 (C=N), 1589
(C=C), 1009 (C-O-C)
1H NMR: 8.01 (s, 1H, H-2 indole),
7.97–7.00 (m, 13H, ArH), 5.45 (dd, 1H,
CH-pyrazoline), 4.42 (q, 2H, CH2),
3.98 (s, 3H, OCH3), 3.88 (dd, 1H,
CH2-pyrazoline equatorial), 3.02 (dd,
1H, CH2-pyrazoline axial), 1.90 (t, 3H,
CH3)
26b 1621 (C=N), 1577
(C=C), 754 (Cl)
1H NMR: 8.21 (s, 1H, H-2 indole),
7.99–7.12 (m, 13H, ArH), 5.40 (dd, 1H,
CH-pyrazoline), 4.45 (q, 2H, CH2),
3.78 (dd, 1H, CH2-pyrazoline equato-
rial), 3.32 (dd, 1H, CH2-pyrazoline ax-
ial), 1.90 (t, 3H, CH3)
27a 1621 (C=N), 1567
(C=C), 1016 (C-O-C)
1H NMR: 8.02 (s, 1H, H-2 indole),
7.68–7.10 (m, 18H, ArH), 5.53 (s, 2H,
CH2), 5.00 (dd, 1H, CH-pyrazoline),
3.99 (s, 3H, OCH3), 3.88 (dd, 1H,
CH2-pyrazoline equatorial), 3.32 (dd,
1H, CH2-pyrazoline axial)
27b 1623 (C=N), 1576
(C=C), 740 (Cl)
461 (M+, 10), 463
(M++2, 4), 144 (40),
105 (60), 91(100)
28a 1687 (C=O), 1645
(C=N), 1587 (C=C),
1010 (C-O-C)
471 (M+, 3), 394 (30),
193 (30), 117 (20), 77
(35)
28b 1670 (C=O), 1621
(C=N), 1566 (C=C),
754 (Cl)
1H NMR: 8.02 (s, 1H, H-2 indole),
8.01–7.10 (m, 18H, ArH), 4.39 (dd, 1H,
CH-pyrazoline), 3.88 (dd, 1H,
CH2-pyrazoline equatorial), 3.32 (dd,
1H, CH2-pyrazoline axial)
29a 1621 (C=N), 1576
(C=C), 1009 (C-O-C)
1H NMR: 8.23 (s, 1H, H-2 indole),
8.01–7.10 (m, 13H, ArH), 5.65 (s, 2H,
CH2), 4.45 (q, 2H, CH2), 4.39 (dd, 1H,
CH-pyrazoline), 3.99 (s, 3H, OCH3),
3.88 (dd, 1H, CH2-pyrazoline equato-
rial), 3.32 (dd, 1H, CH2-pyrazoline ax-
ial), 1.91 (t, 3H, CH3)
29b 1618 (C=N), 1569
(C=C), 750 (Cl)
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30a 1630 (C=N), 1567
(C=C), 1009 (C-O-C)
1H NMR: 8.21 (s, 1H, H-2 indole),
7.99–7.10 (m, 18H, ArH), 5.65 (s, 2H,
CH2), 5.53 (s, 2H, CH2), 4.99 (dd, 1H,
CH-pyrazoline), 4.01 (s, 3H, OCH3),
3.88 (dd, 1H, CH2-pyrazoline equato-
rial), 3.32 (dd, 1H, CH2-pyrazoline
axial)
30b 1621 (C=N), 1577
(C=C), 745 (Cl)
31a 1678 (C=O), 1621
(C=N), 1576 (C=C),
1009 (C-O-C)
31b 1698 (C=O), 1632
(C=N), 1566 (C=C),
754 (Cl)
32a 1602 (C=N), 1575
(C=C), 1021 (C-O-C)
320 (M+, 1), 212 (12),
202 (100), 145 (7), 130
(38), 117 (11)
32b 1634 (C=N), 1594
(C=C), 741 (C-Cl)
324 (M+, 1), 326
(M++2, 0.16), 294 (1),
184 (1), 130 (3), 71
(38), 57 (100).
33a 1608 (C=N), 1517
(C=C), 1182 & 1138 &
1104 (C-O-C)
382 (M+, 1), 264 (31),
207 (12), 131 (5), 115
(5), 91 (100)
33b 1635 (C=N), 1572
(C=C), 736 (C-Cl)
1H NMR: 8.29 (s, 1H, H-2 indole),
8.01–7.12 (m, 13H, ArH), 5.53 (s,
2H, CH2), 5.40 (dd, 1H, CH-isoxa-
zole), 3.78 (dd, 1H, CH2-isoxazole
equatorial), 3.32 (dd, 1H,
CH2-isoxazole axial)
386 (M+, 10), 388
(M++2, 3), 264 (43),
207 (19), 115 (5), 91
(100)
34a 1738 (C=O), 1615
(C=N), 1567 (C=C),
1022 (C-O-C)
1H NMR: 8.21 (s, 1H, H-2 indole),
8.13 (d, 1H, H-7 indole), 7.67–7.00
(m, 12H, ArH), 3.88 (s, 3H, OCH3),
3.71 (dd, 1H, CH-isoxazole), 2.44
(dd, 1H, CH2-isoxazole equatorial),
2.16 (dd, 1H, CH2-isoxazole axial)
396 (M+, 1), 290 (14),
277 (62), 262 (15), 144
(100), 105 (10), 91 (46)
34b 1738 (C=O), 1633
(C=N), 1575 (C=C),
746 (C-Cl)
400 (M+, 10), 402
(M++2, 3), 296 (17),
281 (83), 144 (100),
117 (35), 89 (44), 77
(19)
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11b – 17 14 14 33 –
12a – – – – 14 –
12b – – – 14 – –
13a 8 8 14 – 14 –
13b – 8 – – 14 –
14a 8 8 14 – 14 15
15a – – – – 9 –
15b – – – – – –
16a – 14 14 14 9 –
16b 10 – – – – –
20b – 14 14 – 14 –
22a – 14 – – – –
22b – 14 14 – 14 –
23b – – – – 14 –
24a – – – – 14 –
24b – – – – 14 –
25a – – – – 14 –
25b 14 – 14 – 14 9
26a – – – – – –
26b – – – – 14 –
28a 14 14 14 – 9 –
28b – 14 14 – 14 9
29a – 14 14 – 14 –
30b – – – – 9 –
31a – 15 14 – – –
31b – 14 – – 15 –
32a – 14 14 – 15 –
33a – – 14 – – –
34a – 14 14 – 14 –
34b 14 – 14 – 14 –
Chloramphenicol 42 37 – – – –
Cephalothin – – 38 38 – –
Cycloheximide – – – – 39 40
Inhibition zones: 3–12 mm – low activity, 13–21 mm – moderate activity, > 22 mm – high activity
their in vitro antiproliferative activity against human liver carcinoma HEPG2, (MCF7)
and human colon cancer (HCT-116) cell lines at a concentration of 10 mg mL–1 (Table IV).
Compound 11a was the most active one with antiproliferative activity of 97.6, 100.5 and
99.6 % against HEPG2, MCF7 and HCT-116 cancer cell lines, respectively, whereas com-
pound 11b showed activity of 94.3 % against the HCT-116 cancer cell line and compound
12a of 95.7 % against the MCF7 cancer cell line.
Compounds that showed antiproliferative activity higher than 90 % at concentra-
tion of 10 mg mL–1 were used to calculate their IC50 value, which corresponds to the con-
centration required for 50 % inhibition of cell viability. Doxorubicin, one of the most effec-
tive anticancer agents, was used as a reference drug (Table V). In case of the HEPG2 can-
cer cell line, compound 11a was shown to be more potent with IC50 of 0.7 mmol L–1 than
doxorubicin with IC50 of 40 mmol L–1, for MCF7 cancer cell line, both 11a and 12a were
found to be more potent with IC50 of 0.7 mmol L–1 vs. 0.07 mmol mL–1, whereas in case of
the HCT-116 cancer cell line, again compounds 11a and 11b were found to be more potent
than doxorubicin (IC50 of 60 mmol L–1) with IC50 of 0.7 mmol L–1.
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5a 17.5 7.6 2.1
5b 42.2 6.2 0
6a 61.4 3.9 34.0
6b 27.9 7.8 5.4
7a 42.1 0.65 37.4
7b 57.2 12.9 20.6
8a 47.8 7.7 4.3
8b 0 14.1 0
9a 53.2 19.6 12.5
9b 41.2 18.9 2.9
10a 1.5 22.5 5.0
10b 65.7 25.9 26.6
11a 97.6 100.5 99.6
11b 56.1 60.0 94.3
12a 29.2 95.7 84.2
12b 71.8 28.2 34.9
13a 39.7 6.6 46.7
13b 46.6 0 64.9
Doxorubicin 100.0 100.0 100.0
a Concentration of test compounds and positive control (doxorubicin) 10 mg mL–1
b Untreated cells in DMSO and its final concentration on the cells was less than 0.2 %.
Structure activity relationship (SAR)
From the data obtained it is clear that compound 11a was the most active com-
pound and its activity may be due to the presence of the ethyl donating group at the po-
sition-1 of indole nucleus and the methoxy withdrawing group at the p-position of phe-
nyl moiety. The presence of the withdrawing chlorine atom at the p-position of phenyl
moiety in 11b is associated with the remarkable antiproliferative activity against the
HCT-116 cancer cell line only, whereas the presence of the benzyl withdrawing moiety
as in 12a is associated with the remarkable antiproliferative activity against the MCF7
cancer cell line.
CONCLUSIONS
A series of pyrimidin-2(1H)ones 5a,b-7a,b, pyrimidin-2(1H)-thiones 8a,b-10a,b, py-
rimidin-2-amines 11a,b-13a,b, cyclohexanone derivatives 14a,b-16a,b, indazole derivati-
ves 17a,b-19a,b, pyrazole derivatives 20a,b-31a,b and isoxazole derivatives 32a,b-34a,b
incorporated into N-alkylindole at their 3-positions were prepared. 4-(N-Ethyl-1H-indol-
-3-yl)-6-(p-chlorophenyl)-pyrimidin-2-amine (11b) was found to be the most active of all
test compounds towards Candida albicans, whereas compound 4-(N-ethyl-1H-indol-3-yl)-
-6-(p-methoxyphenyl)-pyrimidin-2-amine (11a) was found to be the most active one aga-
inst HEPG2, MCF7 and HCT-116 cancer cell lines with IC50 values of 0.7 mmol L–1.
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11a 0.0007 0.0007 0.0007
11b – – 0.0007
12a – 0.0007 –
Doxorubicin 0.04 0.07 0.06
IC50 – Concentration required to inhibit cell viability by 50 %.
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S A @ E T A K
Sinteza, antimikrobno i antitumorsko djelovanje nekoliko novih
N-etil, N-benzil i N-benzoil-3-indolil heterocikli~kih spojeva
ESLAM REDA EL-SAWY, ADEL HAMED MANDOUR, KHALED MAHMOUD,
INAS EZZ-ELDIN ISLAM i HEBA MOHAMED ABO-SALEM
Sintetizirana je serija 1-(N-supstituiranih-1H-indol-3-il)-3-arilprop-2-en-1-ona (2a,b-4a,b) i
podvrgnuta reakciji s ureom, tioureom ili gvanidinom, pri ~emu su nastali derivati piri-
midina 5a,b–13a,b. Reakcijom 2a,b-4a,b s etil-acetoacetatom u prisutnosti baze nastali su
derivati cikloheksanona 14a,b-16a,b. Njihovom reakcijom s hidrazin hidratom dobiveni
su derivati indazola 17a,b-19a,b. S druge strane, reakcijom 2a,b-4a,b s odre|enim deri-
vatima hidrazina, tj. s hidrazin hidratom, acetil hidrazinom, fenilhidrazinom i benzilhi-
drazin hidrokloridom, nastali su derivati pirazola 20a,b-31a,b. Nadalje, reakcijom 2a,b-4a,b
s hidroksilamin hidrokloridom dobiveni su derivati izoksazola 32a,b-34a,b. Pripravljeni
spojevi ispitani su na antimikrobno djelovanje. Pokazalo se da je 4-(N-etil-1H-indol-3-
-il)-6-(p-klorfenil)-pirimidin-2-amin (11b) najaktivniji spoj za Candida albicans (ATCC 10231)
uz cikloheksimid kao poredbeni lijek. Testirano je antitumorsko djelovanje in vitro osam-
naest novih spojeva, tj. pirimidin-2(1H)-ona 5a,b-7a,b, pirimidin-2(1H)-tiona 8a,b-10a,b i
pirimidin-2-amina 11a,b-13a,b na tumorske stanice HEPG2, MCF7 i HCT-116. Najaktiv-
niji spoj bio je 4-(N-etil-1H-indol-3-il)-6-(p-metoksifenil)-pirimidin-2-amin (11a) uz IC50
0,7 mmol L 1.
Klju~ne rije~i: N-supstituirani-3-indolilkalkoni, heterocikli~ki spojevi, antimikrobno djelovanje, anti-
tumorsko djelovanje
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